

Invitation to Contribute & Study Opening Announcement

“Sequential Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Multicenter Prospective Phase 2 Trial”

Led by Dr. Michael O'Donnell





Director of Urologic Oncology, University of Iowa, US

Dear Colleagues,

We are excited to announce the opening of a new national and international **prospective clinical trial** evaluating the efficacy of intravesical gemcitabine/docetaxel in patients with BCG-unresponsive NMIBC.

This study is led by **Dr. Michael O'Donnell**, a global leader in urologic oncology and the innovator behind the widely adopted gemcitabine/docetaxel regimen. His work has transformed care for NMIBC patients, especially during the global BCG shortage.

You're invited to be part of this important global study:

-  Join a worldwide network of national and international research sites
-  Contribute to advancing cutting-edge therapies for patients everywhere
-  Support clinical research in areas with limited access to NMIBC trials
-  Collaborate with leading experts to shape the future of treatment standards

Study Focus:

Intravesical Gemcitabine/Docetaxel for BCG-Unresponsive NMIBC

Interested in Participating?

Please contact us to express your interest and receive the study protocol and site requirements:

 Gemdocetrial@outlook.com

Let's work together to bring this vital research to our region.

Your contribution can make a lasting impact.